Bank of America Corp. (BAC): Director Robert W Scully Bought 62,000 Shares
Director of Bank of America Corp., Robert W Scully, bought 62,000 shares on 10/21/09 at an average price of $16.22.
Bank of America Corp. is one of the world's leading financial services companies. The company provides individuals, small businesses, and commercial, corporate, and institutional clients around the world innovative ways to manage their financial lives. Bank Of America Corp. has a market cap of $131.03 billion; its shares were traded at around $16.22 with a P/E ratio of 27.1 and P/S ratio of 1.8. The dividend yield of Bank Of America Corp. stocks is 0.2%. Bank Of America Corp. had an annual average earning growth of 7.5% over the past 10 years.
On October 16, Bank of America Corp. reported a third-quarter 2009 net loss of $1.0 billion. Those results compared with net income of $1.2 billion, or diluted earnings per share of $0.15, during the year-ago period.
Bank of America Corp. is in the portfolios of 24 Gurus: John Paulson, Daniel Loeb, Andreas Halvorsen, Ken Heebner, George Soros, Richard Snow, Hotchkis & Wiley, Charles Brandes, Ronald Muhlenkamp, Bill Nygren, Irving Kahn, Warren Buffett, Tom Gayner, Brian Rogers, Chris Davis, Ruane Cunniff, Arnold Schneider, David Tepper, Donald Yacktman, Kenneth Fisher, Richard Pzena, John Keeley, David Dreman, and Dodge & Cox.
Last week, Buy:: Director Robert W Scully bought 62,000 shares of BAC stock, and the price has decreased by 3.39% since. Buy:: Pres, Glbl Wealth and Inv Mgmt Sallie Krawcheck bought 63,000 shares in August.
Safeway Inc. (SWY): Director Kenneth W. Oder Bought 10,000 Shares
Director of Safeway Inc., Kenneth W. Oder, bought 10,000 shares on 10/22/09 at an average price of $22.4.
Safeway Inc. is a food and drug retailer in North America. The company operates stores under a variety of names, including Vons Dominick's and Randalls/Tom Thumb. In support of its stores, Safeway has an extensive network of distribution, manufacturing, and food processing facilities. Safeway Inc. has a market cap of $8.65 billion; its shares were traded at around $22.4 with a P/E ratio of 10.2 and P/S ratio of 0.2. The dividend yield of Safeway Inc. stocks is 1.9%. Safeway Inc. had an annual average earning growth of 9.8% over the past 5 years.
On October 15, Safeway Inc. reported net income of $128.8 million ($0.31 per diluted share) for the third quarter of 2009 compared to net income of $199.7 million ($0.46 per diluted share) for the third quarter of 2008. Total sales declined 7.0% to $9.5 billion in the third quarter of 2009 compared to $10.2 billion in the third quarter of 2008.
Safeway Inc. is in the portfolios of HOTCHKIS & WILEY of HOTCHKIS & WILEY Capital Management LLC and Charles Brandes of Brandes Investment.
Last week, both Buy:: Director Kenneth W. Oder and Buy:: Director Michael S Shannon bought shares of SWY stock; the price has decreased more than 2% since. Buy:: Director Janet Grove bought 1,500 in May, and Sell:: Executive Vice President Bruce L Everette and Sell:: Senior Vice President on 10/15/2009 Jerry Tidwell sold shares this month.
Umpqua Holdings Corp. (UMPQ): Director Frank R J Whittaker Bought 4,000 Shares
Director of Umpqua Holdings Corp., Frank R J Whittaker, bought 4,000 shares on 10/21/09 at an average price of $9.88.
Umpqua Holdings Corp. is a financial holding company. Through its subsidiaries, the company engages primarily in the business of commercial and retail banking and the delivery of retail brokerage services. Umpqua Holdings Corp. has a market cap of $781 million; its shares were traded at around $9.88 with a P/E ratio of 78.1 and P/S ratio of 1.5. The dividend yield of Umpqua Holdings Corp. stocks is 2.2%. Umpqua Holdings Corp. had an annual average earning growth of 3.8% over the past 5 years.
On October 15, Umpqua Holdings Corporation announced a third quarter 2009 net loss of $7.1 million. Including preferred stock dividends of $3.2 million, the net loss available to common shareholders was $10.4 million, or $0.14 per diluted share.
Last week, Buy:: Director Frank R J Whittaker bought 4,000 shares of UMPQ stock; the price increased by 1.54%.
National Penn Bancshares Inc. (NPBC): Director Christian F IV Martin Bought 1,637 Shares
Director of National Penn Bancshares Inc., Christian F IV Martin, bought 1,637 shares on 10/16/09 at an average price of $6.17.
National Penn Bancshares Inc. is a bank holding company engaged in general banking business. National Penn Bancshares Inc. has a market cap of $719.2 million; its shares were traded at around $6.17 with and P/S ratio of 1.6. The dividend yield of National Penn Bancshares Inc. stocks is 3.4%. National Penn Bancshares Inc. had an annual average earning growth of 5.4% over the past 10 years. GuruFocus rated National Penn Bancshares Inc. the business predictability rank of 2.5-star.
National Penn Bancshares, Inc. announced that it plans to release its 3rd Quarter 2009 earnings on Thursday, October 29, 2009, at 9 a.m. Eastern time. The related earnings Webcast will be broadcast live over the Internet on October 29th at 1 p.m. Eastern time. National Penn Bancshares presenters will be Glenn E. Moyer, president and CEO; Scott V. Fainor, COO; and Michael J. Hughes, CFO. Michelle H. Debkowski, corporate secretary and investor relations officer, will serve as moderator.
National Penn Bancshares Inc. is in the portfolio of one Guru: David Dreman of Dreman Value Management.
In July, Buy:: President and CEO Glenn E Moyer bought 2,650 shares of NPBC stock, and the price increased by 32.69%. Buy:: Director bought 1,637 shares this month. Buy:: Director on Molly K Morrison, Buy:: Director Natalye Paquin, and Buy:: Director Christian F Iv Martin all bought shares in September; Buy:: Director Albert H Kramer bought 1,944 shares in August.
Enzo Biochem Inc. (ENZ): President, Enzo Clinical Labs Kevin Krenitsky Bought 6,600 Shares
President, Enzo Clinical Labs of Enzo Biochem Inc., Kevin Krenitsky, bought 6,600 shares on 10/15/09 at an average price of $6.76.
Enzo Biochem Inc. develops, manufactures, and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. Enzo Biochem Inc. has a market cap of $239.8 million; its shares were traded at around $6.76 with and P/S ratio of 3.1.
On October 14, Enzo Biochem, Inc. reported a 16% increase in total operating revenue, to $24.5 million, and a 19% increase in gross profit, to $10.6 million, for the fourth fiscal quarter ended July 31, over the comparable quarter last year. The net loss was $5.3 million or ($0.14) per share, compared to a year ago net loss of $3.3 million, or ($0.09) per share.
This month, Buy:: President, Enzo Clinical Labs Kevin Krenitsky bought 6,600 shares of ENZ stock, and the price of the stock has decreased by 12.21% since[b][/b]
Become a Premium Member to See This: (Free Trial):
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys:: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
Rate This Article: |
  |